Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Revenue:
Net product sales		$ 149,418		$ 218,740
Consulting research & development income	105,426	7,500	177,426	43,192
Shipping and other sales	2,500		5,000
Total revenues	107,926	156,918	182,426	261,932
Cost of goods sold	901	69,988	3,485	129,074
Gross profit	107,025	86,930	178,941	132,858
Operating expenses:
Research and development expenses	733,167	376,840	1,094,037	803,369
Selling, general and administrative expenses	3,011,346	2,033,761	5,376,432	3,052,271
Change in fair value of contingent stock consideration	8,520,000		8,520,000
Total operating expenses	12,264,513	2,410,601	14,990,469	3,855,640
Net operating loss before other income (expense)	(12,157,488)	(2,323,671)	(14,811,528)	(3,722,782)
Other income (expense):
Interest income	3,138		3,138
Other income	15,000	86	15,000	7,619
Gain on deconsolidation	80,868		80,868
Change in fair value of derivative liability	425,622	181,610	273,003	206,387
Other expense	(319,069)	(1,826)	(590,270)	(109,707)
Interest expense	(699,485)	(266,429)	(3,996,964)	(700,259)
Loss on conversion of convertible promissory notes			(3,659,518)
Other income (expense)	(493,926)	(86,559)	(7,874,743)	(595,960)
Net loss before income taxes	(12,651,414)	(2,410,230)	(22,686,271)	(4,318,742)
Provision for income taxes
Net loss	(12,651,414)	(2,410,230)	(22,686,271)	(4,318,742)
Net loss attributable to non-controlling interest	(3,807)	(7,903)	(10,496)	(14,578)
Net loss attributable to Cure Pharmaceutical Holding Corp.	$ (12,647,607)	$ (2,402,327)	$ (22,675,775)	$ (4,304,164)
Net loss per share, basic and diluted	$ (0.36)	$ (0.10)	$ (0.73)	$ (0.18)
Weighted average common shares outstanding
Basic and Diluted	35,345,442	24,217,808	31,088,381	24,210,688